3wzq: Difference between revisions
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of the core streptavidin mutant V212 (Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N) complexed with iminobiotin long tail (IMNtail) at 1.7 A resolution== | ==Crystal structure of the core streptavidin mutant V212 (Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N) complexed with iminobiotin long tail (IMNtail) at 1.7 A resolution== | ||
<StructureSection load='3wzq' size='340' side='right' caption='[[3wzq]], [[Resolution|resolution]] 1.70Å' scene=''> | <StructureSection load='3wzq' size='340' side='right'caption='[[3wzq]], [[Resolution|resolution]] 1.70Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3wzq]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3WZQ OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[3wzq]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Streptomyces_avidinii Streptomyces avidinii]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3WZQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3WZQ FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=P6G:HEXAETHYLENE+GLYCOL'>P6G</scene>, <scene name='pdbligand=ZOF:6-({5-[(2E,3AS,4S,6AR)-2-IMINOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-4-YL]PENTANOYL}AMINO)HEXANOIC+ACID'>ZOF</scene> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.7Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=P6G:HEXAETHYLENE+GLYCOL'>P6G</scene>, <scene name='pdbligand=ZOF:6-({5-[(2E,3AS,4S,6AR)-2-IMINOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-4-YL]PENTANOYL}AMINO)HEXANOIC+ACID'>ZOF</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3wzq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3wzq OCA], [https://pdbe.org/3wzq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3wzq RCSB], [https://www.ebi.ac.uk/pdbsum/3wzq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3wzq ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/SAV_STRAV SAV_STRAV] The biological function of streptavidin is not known. Forms a strong non-covalent specific complex with biotin (one molecule of biotin per subunit of streptavidin). | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 19: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 3wzq" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 3wzq" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Avidin 3D structures|Avidin 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Doi | [[Category: Large Structures]] | ||
[[Category: Inoue | [[Category: Streptomyces avidinii]] | ||
[[Category: Kanai | [[Category: Doi H]] | ||
[[Category: Kawato | [[Category: Inoue T]] | ||
[[Category: Kodama | [[Category: Kanai M]] | ||
[[Category: Matsumura | [[Category: Kawato T]] | ||
[[Category: Matsuoka | [[Category: Kodama T]] | ||
[[Category: Meshizuka | [[Category: Matsumura H]] | ||
[[Category: Mizohata | [[Category: Matsuoka M]] | ||
[[Category: Shimizu | [[Category: Meshizuka T]] | ||
[[Category: Sugiyama | [[Category: Mizohata E]] | ||
[[Category: Takasu | [[Category: Shimizu Y]] | ||
[[Category: Tsumoto | [[Category: Sugiyama A]] | ||
[[Category: Yamamoto | [[Category: Takasu N]] | ||
[[Category: Tsumoto K]] | |||
[[Category: Yamamoto T]] | |||
Latest revision as of 16:35, 8 November 2023
Crystal structure of the core streptavidin mutant V212 (Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N) complexed with iminobiotin long tail (IMNtail) at 1.7 A resolutionCrystal structure of the core streptavidin mutant V212 (Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N) complexed with iminobiotin long tail (IMNtail) at 1.7 A resolution
Structural highlights
FunctionSAV_STRAV The biological function of streptavidin is not known. Forms a strong non-covalent specific complex with biotin (one molecule of biotin per subunit of streptavidin). Publication Abstract from PubMedFor a multistep pre-targeting method using antibodies, a streptavidin mutant with low immunogenicity, termed low immunogenic streptavidin mutant No. 314 (LISA-314), was produced previously as a drug delivery tool. However, endogenous biotins (BTNs) with high affinity (Kd < 10-10 M) for the binding pocket of LISA-314 prevents access of exogenous BTN-labelled anticancer drugs. In this study, we improve the binding pocket of LISA-314 to abolish its affinity for endogenous BTN species, therefore ensuring that the newly designed LISA-314 binds only artificial BTN analogue. The replacement of three amino acid residues was performed in two steps to develop a mutant termed V212, which selectively binds to 6-(5-((3aS,4S,6aR)-2-iminohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)hex anoic acid (iminobiotin long tail, IMNtail). Surface plasmon resonance results showed that V212 has a Kd value of 5.9 x 10-7 M towards IMNtail, but no binding affinity for endogenous BTN species. This V212/IMNtail system will be useful as a novel delivery tool for anticancer therapy. Structure-based design of a streptavidin mutant specific for an artificial biotin analogue.,Kawato T, Mizohata E, Shimizu Y, Meshizuka T, Yamamoto T, Takasu N, Matsuoka M, Matsumura H, Kodama T, Kanai M, Doi H, Inoue T, Sugiyama A J Biochem. 2015 Feb 2. pii: mvv004. PMID:25645976[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||